“…Because of the therapeutic values in AML, the discovery of FLT3 inhibitors has increasingly attracted much attention in recent years. To date, several FLT3 inhibitors including SU-5416, 12 SU-11248, 13 CHIR-258, 14 PKC-412, 15 CEP-701, 16 MLN-518, 17 BAY-43-9006, 18 KW-2449, 19 and AC220 20 have been advanced to clinical trials. However, except for very few of them, such as AC220, the clinical efficacy of most of these FLT3 inhibitors in patients with AML seems unimpressive, mainly because of their potency and/or adverse events that stem from their poor target selectivity.…”